Background
Cardiac radionuclide imaging has wide applications such as diagnosis, disease severity assessment, decisions regarding treatment strategies, evaluation of treatment effects, and prognosis of cardiac diseases. The aim of these guidelines is the effective and efficient use of cardiac radionuclide imaging in the diagnosis of cardiac diseases. To that end, we have summarized the usefulness and evidence levels of diagnostic test techniques on the basis of previous reports. The characteristics and usefulness of each diagnostic test technique are outlined in the first half of the guidelines, and the use of radionuclide imaging in specific cardiac diseases and pathologies is addressed in the second half.
Basic Principles
This working groups discussed the appropriate use of nuclear cardiology in the clinical setting based on previous reference to the Report of the Committee on Diagnostic Criteria for the Diagnosis of Cardiac Diseases with Nuclear Medicine Techniques (1989 ( -1991 and the Standardization of Clinical Indication of New Radiopharmaceutical Agents for Circulatory Organs (1998, Sugishita et al.) . Whereas the guidelines for cardiac radionuclide imaging were published by the American Heart Association (AHA), American College of Cardiology (ACC) and American Society of Nuclear Cardiology (ASNC) in 2003, 1 the guidelines for cardiac radionuclide imaging in Japan were proposed on the basis of a detailed review of reports published in Japan in addition to reports from Europe and the United States. The working groups revised the guidelines published in fiscal year 2005 to incorporate new knowledge in the area of nuclear cardiology from the subsequent five years. To provide researchers with the latest reports in the literature, related research papers published in English were retrieved through a computer search. As a result, we cited over 1,000 research papers for this revised guidelines. We decided a literature searching period for each imaging technique on a case by case basis. After a detailed review of selected papers, we
Guidelines for Clinical Use of Cardiac Nuclear Medicine (JCS 2010)
-Digest Version -JCS Joint Working Group The working groups discussed at length the classification and evidence levels. There were some conflicting issues in terms of indications and classification. We addressed the minority opinion of members as well. The tables of classification and evidence levels that overlap in the first edition of the guidelines were organized to be more easily understood. Moreover, new descriptions were added for areas in which the significance of cardiac radionuclide imaging has recently become evident. The usefulness of cardiac radionuclide imaging was classified as follows in accordance with the conventional guidelines. 1 The Japanese Circulation Society (JCS) classifications I, II, and III are used to summarize test indications as follows ( Table 1) .
This revised cardiac nuclear medicine guidelines were reviewed by the independent assessment committee, and was approved by the JCS and other collaborating societies. This revised guideline will be published on the JCS website. Moreover, we have made the digest version in order to make full guideline more widespread. This digest version of guideline is also intended to assist physicians in applying cardiac nuclear medicine in clinical settings and to assist to accessing important previous publications.
Imaging Techniques
Imaging techniques were categorized in accordance with radiopharmaceutical agents used in radionuclide imaging. We added new sections such as electrocardiogram (ECG) gating, positron emission tomography (PET), and image fusion techniques to these updated guidelines. We also addressed the classification of the uses of radionuclide imaging in stress tests and in pediatric cases. Myocardial perfusion imaging techniques were categorized into Tl-201-labeled and Tc-99 m labeled myocardial perfusion imaging techniques. 2 In addition, myocardial sympathetic nerve imaging using I-123-metaiodobenzylguanidine (I-123 MIBG), myocardial fatty acid metabolism imaging using I-123-beta-methyl-p-iodophenylpentadecanoic acid (I-123 BMIPP), Ga-67 citrate and Tc-99 m pyrophosphate imaging were also addressed.
Selection of Diagnostic Test Techniques Depending on Pathologies and Diseases
These guidelines address the selection of diagnostic test techniques in acute coronary syndrome (ACS), chronic coronary artery diseases, heart failure, and myocardial viability assessment.
II Practical Guidelines: Imaging Techniques
Myocardial Perfusion Imaging
Myocardial perfusion imaging has been established as a major diagnostic technique in nuclear cardiology. It enables the simple and noninvasive assessment of myocardial ischemia and reduction of coronary flow reserve using exercise or pharmacological stress. 3, 4 Myocardial perfusion imaging provides functional information on coronary arteries, which is different from the morphological information provided by coronary angiography. Moreover, it is suitable for the quantitative evaluation of myocardial perfusion conditions. ECG gated singlephoton emission computed tomography (SPECT) provides information on myocardial perfusion and left ventricular (LV) function. 5 It is widely used for coronary artery disease detection in clinical practice including the diagnosis of myocardial ischemia and infarction, assessment of severity, assessment of myocardial viability, determination of indication of a revascularization procedure, and assessment of treatment effects. 6-10 It is also used for assessment of pathologies and to determine the severity of heart failure and cardiomyopathy. Moreover, there is a large amount of data supporting the usefulness of this 
Myocardial Sympathetic Nerve
Imaging Using I-123 MIBG I-123 MIBG reflects the distribution of cardiac sympathetic nerve terminals. Thus, using I-123 MIBG it is possible to detect local denervation. 17 The clearance of I-123 MIBG from the heart reflects sympathetic nerve activity. Thus, an increase in rate of clearance is associated with increasing sympathetic nerve activity due to heart failure. When considering the assessment of prognosis in patients with heart failure, most previous studies have focused on dilated cardiomyopathy. 18, 19 However, it has been reported that I-123 MIBG imaging is also useful for assessment of prognosis in patients with heart failure associated with ischemic heart diseases. 20 It should be noted that in patients with diabetes, decrease in I-123 MIBG accumulated uptake in the LV inferior wall can be observed even in the absence of cardiac disease. 21 Recommendations for myocardial sympathetic nerve imaging are as follows ( Table 3) .
Myocardial Fatty Acid Metabolism Imaging Using I-123 BMIPP
This technique is useful for the diagnosis of unstable angina and is highly useful for the diagnosis of early phase of ACS. 22 It is also useful for the detection of ischemic myocardial damage (i.e. ischemic memory imaging) in patients with difficulty undergoing stress tests. 23 I-123 BMIPP may be useful in the diagnosis of coronary vasospastic angina. 24 Differences in myocardial blood perfusion and I-123 BMIPP uptake are sometimes observed in stunned 25 and hibernating myocardium. 26 Thus, this technique is useful in assessing the pathology of myocardial ischemia. 27 I-123 BMIPP may be useful for predicting cardiovascular events. 28 Recommendations for myocardial fatty acid metabolism imaging are as follows ( Table 4 ).
Inflammation Imaging Using Ga-67 Citrate
Ga-67 citrate is used for the assessment of myocardial lesions in patients with cardiac sarcoidosis and for the auxiliary diagnosis of myocarditis and infective endocarditis. 1 
Cardiac Radionuclide Angiography
Cardiac radionuclide angiography (RNA) is widely used as a highly accurate method of assessing cardiac function. 29 Recently, with improvements in the accuracy and technology of echocardiography and the spread of ECG gated SPECT, the use of cardiac RNA has decreased in Japan. However, cardiac RNA at rest is widely applied in the United States for the detection of cardiac toxicity during chemotherapy. 30 Cardiac RNA should be more widely used in Japan, particularly in the above clinical setting.
Recommendations for cardiac RNA are listed above ( Table 5 ).
Positron Emission Tomography
The usefulness of cardiac PET has been established for diagnosis of myocardial viability using 18 F fluorodeoxyglucose (F-18 FDG) 31 and the diagnosis of coronary artery diseases using myocardial perfusion imaging. 31-33 Rubidium-82 and N-13 ammonia are used in clinical practice in North America. 34 Moreover, there has recently been accumulation of evidence for the usefulness of stress myocardial perfusion PET in the prognosis of cardiovascular events. 35 PET enables the quantitative evaluation of myocardial blood flow and the assessment of myocardial blood flow reserve. Thus, PET can be used for assessment of the severity of ischemic heart diseases and the quantitative diagnosis of myocardial microcirculatory disorders. 36 PET can also be used for the detection of lesions in the early phase of arteriosclerosis and the determination of treatment effects. 37 Recommendations for F-18 FDG PET and myocardial perfusion PET are listed above ( Table 6 ).
Stress Tests
Stress tests can be roughly divided into exercise stress tests and pharmacological stress tests. 2 Dipyridamole, adenosine, and adenosine triphosphate (ATP) with a coronary dilation effect are used as pharmacological stress agents. 38 Exercise stress tests are usually recommended and used if patients can exercise. 39 Pharmacological stress tests are used in cases in which exercise stress tests are not suitable. It is important to understand the characteristics of stress tests and to evaluate the myocardial perfusion imaging taking into consideration symptoms during stress tests and ECG findings.
Recommendations for stress protocols are listed above ( Table 7) .
Beginning in June 2005, the government of Japan, through the National Health Insurance program, approved the use of adenosine as a stress agent for myocardial stress perfusion imaging and provided financial reimbursement for its use. Prior to this date the Ministry of Health, Labour and Welfare had not approved any agents for stress test myocardial perfusion imaging.
Characteristics and Precautions in Pediatric Cases
Indications of myocardial perfusion imaging in pediatric cases include congenital coronary artery diseases, acquired coronary artery diseases (mainly Kawasaki disease), cardiomyopathy, myocardial damage, and right ventricular pressure overload. 40, 41 Pharmacological stress tests may be more appropriate than exercise stress tests in many cases. It is necessary to consider the specificity of the imaging for pediatric cases when performing myocardial perfusion imaging and making a diagnosis in pediatric patients. 42 Recommendations for pediatric cases are listed above ( Table 8) .
III Clinical Use of Radionuclide Imaging in Specific Cardiac Diseases and Pathologies

Acute Coronary Syndrome
Tc-99 m-labeled myocardial perfusion imaging is used for the diagnosis of chest pain suspected to be ACS. It has been reported that with the administration of Tc-99 m-labeled myocardial perfusion agents in the acute phase, the imaging of an area of at-risk myocardium and the subsequent assessment of myocardial salvage by follow-up myocardial imaging are useful. 43, 44 However, there are a limited number of hospitals that provide Tc-99 m-labeled myocardial perfusion imaging in the emergency department. Myocardial perfusion imaging performed in the early phase of ACS is important for risk stratification. It has been reported that diagnostic performance is improved by using myocardial perfusion imaging in combination with ECG gating. 45 The diagnostic accuracy of myocardial fatty acid metabolism imaging using I-123 BMIPP is equivalent to that of myocardial perfusion imaging in cases of acute myocardial infarction. I-123 BMIPP has higher diagnostic accuracy compared to rest myocardial perfusion imaging in cases of unstable angina. 46 Myocardial imaging using I-123 BMIPP at rest is highly useful in patients with ACS in the early phase, which stress tests are difficult to perform ( Table 9) . 47 
Chronic Coronary Artery Diseases
Myocardial perfusion imaging is particularly useful for detecting coronary artery diseases in patients with intermediate pre- 
Heart Failure
While cardiac RNA has been widely used in the assessment of cardiac functions, the number of cardiac RNA studies has decreased with the improvement in accuracy of cardiac function measurement by echocardiography and the increased use of ECG gated SPECT. Quantitative gated SPECT (QGS) allows for the assessment of cardiac function during myocardial perfusion imaging. Myocardial perfusion imaging can be used to determine the presence of ischemic versus nonischemic heart diseases as the cause of heart failure. It has been reported that the simultaneous assessment of myocardial blood perfusion and myocardial wall motion by ECG gated imaging improves diagnostic performance. 51 Findings of myocardial perfusion abnormalities are also useful in the assessment of severity of heart failure. Myocardial sympathetic nerve imaging using I-123 MIBG is useful for assessment of severity, 52 determination of treatment effects, 53 and prediction of cardiac events. 18,19,54
Myocardial Viability Assessment
Myocardial perfusion imaging and F-18 FDG PET are used in the assessment of myocardial viability. 55, 56 In order to determine myocardial viability in patients with reduced wall motion and a decreased LV ejection fraction, the presence or absence of a perfusion/metabolism mismatch is examined using myocardial perfusion imaging and F-18 FDG PET. In the case of a perfusion/metabolism mismatch with viable myocardium, adequate revascularization may improve wall motion, LV function and outcomes. 31,57 F-18 FDG PET is useful in determining indication of the revascularization procedure. 
